TAS::75 0849::TAS SBIR TOPIC 304 PHASE I "DEVELOPMENT OF BLOOD-BASED METHODS FOR

TAS::75 0849::TAS SBIR 主题 304 第一阶段“基于血液的方法的开发

• 批准号: 8342473
• 负责人: LING TIAN
• 金额: $ 29.86万
• 依托单位: MEDIOMICS, LLC
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-30 至 2012-06-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8342473
• 关键词: Adjuvant Therapy; American Cancer Society; Biological Assay; Biological Markers; Blood; Cancerous; Cessation of life; Clinical; Development; Diagnosis; Diagnostic Neoplasm Staging; Disease; ERBB2 gene; Early Diagnosis; Enzyme-Linked Immunosorbent Assay; Goals; Methods; Operative Surgical Procedures; Patients; Phase; Prevention; Recurrence; Recurrent disease; Risk; Sampling; Screening procedure; Serum; Small Business Innovation Research Grant; Specificity; Testing; Tissues; Tumor stage; United States; Validation; Woman; base; cancer recurrence; cost effective; fight against; improved; malignant breast neoplasm; molecular marker; therapeutic target

According to the American Cancer Society, 192,370 women in the United States will be diagnosed with invasive breast cancer in 2010, leading to 40,170 deaths. Most women with breast cancer undergo surgery to remove the cancerous tissue and then receive additional treatment. Adjuvant therapy does not completely remove the risk of late cancer recurrence, even for women with low grade/low stage tumors. Thus, clinicians and patients still need to remain aware of this problem and this problem remains a high priority in our fight against breast cancer. In the past decades, identification and validation of ER, PR and HER2 as molecular markers and therapeutic targets for breast cancer has improved the patient survival. However, other breast cancer biomarkers currently identified lack either disease-related specificity or validated clinical values. Therefore, effective new breast cancer-specific molecular markers for prevention, early detection, and/or targeted treatment of the recurrent diseases are needed. Biomarkers present in blood, hold the best promise for disease screening. The goal of this project is to develop simple, quick and cost-effective homogeneous assays to evaluate whether AKR1B10 can be used as a breast cancer recurrence indicator by testing the serum samples from both cancer-recurrence positive and negative patients.

根据美国癌症协会的数据，2010年美国将有192,370名妇女被诊断患有浸润性乳腺癌，导致40,170人死亡。大多数患有乳腺癌的妇女都接受手术切除癌组织，然后接受额外的治疗。辅助治疗并不能完全消除晚期癌症复发的风险，即使对于低级别/低阶段肿瘤的妇女也是如此。因此，临床医生和患者仍然需要意识到这个问题，这个问题仍然是我们与乳腺癌斗争的重中之重。在过去的几十年里，ER、PR和HER2作为乳腺癌的分子标记物和治疗靶点的识别和验证提高了患者的生存率。然而，目前发现的其他乳腺癌生物标志物缺乏与疾病相关的特异性或经过验证的临床价值。因此，需要有效的新的乳腺癌特异性分子标记物来预防、早期发现和/或靶向治疗复发性疾病。血液中存在的生物标记物是疾病筛查的最佳选择。该项目的目标是通过检测癌症复发阳性和阴性患者的血清样本，开发简单、快速和具有成本效益的均质检测方法，以评估AKR1B10是否可以作为乳腺癌复发指标。